CK19和甲状腺过氧化物酶表达在甲状腺疾病诊断中的作用

南方医科大学学报 ›› 2005, Vol. 25 ›› Issue (06): 678-681.

CK19和甲状腺过氧化物酶表达在甲状腺疾病诊断中的作用

杨清绪¹, 邵春奎², 冯智英², 黄本强³, 韩安家⁴, 熊敏⁴, 赵文丽¹, 武彤彤¹

1. 惠州市中心人民医院, 病理科, 广东, 惠州, 516001;
2. 中山大学附属第三医院病理科, 广东, 广州, 510630;
3. 惠州市中心人民医院, 普外科, 广东, 惠州, 516001;
4. 中山大学医学院病理学教研室, 广东, 广州, 510089

出版日期:2005-06-20 发布日期:2005-06-20
基金资助:
收稿日期:2004-12-22。
基金项目:广东省医学科研基金(A2004753)
作者简介:杨清绪(1963- ),男,硕士,副主任医师,电话:0752-2288244,E-mail:HZBingli@126.com

Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases

YANG Qing-xu¹, SHAO Chun-kui², FENG Zhi-ying², HUANG Ben-qiang³, HAN An-jia⁴, XIONG Min⁴, ZHAO Wen-li¹, WU Tong-tong¹

1. 惠州市中心人民医院, 病理科, 广东, 惠州, 516001;
2. 中山大学附属第三医院病理科, 广东, 广州, 510630;
3. 惠州市中心人民医院, 普外科, 广东, 惠州, 516001;
4. 中山大学医学院病理学教研室, 广东, 广州, 510089

Online:2005-06-20 Published:2005-06-20

摘要/Abstract

摘要： 目的探讨CK19和甲状腺过氧化物酶(TPO)在甲状腺癌和良性甲状腺病变中的表达情况,以提高甲状腺癌的诊断和鉴别诊断水平。方法应用SP免疫组织化学法检测了62例甲状腺癌(30例典型乳头状癌、22例滤泡型乳头状癌和10例滤泡型癌)和44例良性甲状腺病变(22例结节性甲状腺肿、14例甲状腺腺瘤和8例桥本氏甲状腺炎)中CK19和TPO的表达。结果 CK19在甲状腺癌中表达率为96.8%,在良性甲状腺病变中极少表达或小灶性弱表达,表达率为4.5%,两者有显著性差异(P<0.01);TPO在良性甲状腺病变中的表达率为100%,在甲状腺癌中极少表达或小灶性表达,表达率为3.2%,两者有显著性差异(P<0.01)。结论 CK19和TPO在甲状腺癌的病理诊断和鉴别诊断中具有重要意义和临床实用价值。

Abstract: Objective To investigate the value of detecting cytokeratin 19(CK19) and thyroperoxidase (TPO) expression in the diagnosis of thyroid diseases including thyroid carcinoma, multinodular goiter, adenoma and Hashimoto thyroiditis. Methods SP immunohistochemistry was used to detect the expressions of CK19 and TPO in paraffin-embedded thyroid tissue specimens obtained from 62 patients with thyroid carcinoma (30 with papillary carcinomas, 22 with follicular variant of papillary carcinomas, and 10 with follicular carcinomas) and 44 with benign thyroid diseases (including 22 with multinodular goiters, 14 with adenoma, and 8 with Hashimoto thyroiditis). Results CK19 expression was detected in 96.8% of the thyroid carcinomas and in 4.5% of benign thyroid diseases, demonstrating a significant difference in CK19 expression between the two thyroid diseases (P<0.01). TPO expression was found in 100% of benign thyroid disease and in 3.2% of thyroid carcinoma, showing also a significant difference between them (P<0.01). Conclusion CK19 and TPO can be important molecular markers for diagnosing thyroid carcinoma.

中图分类号:

R736.1

杨清绪¹, 邵春奎², 冯智英², 黄本强³, 韩安家⁴, 熊敏⁴, 赵文丽¹, 武彤彤¹. CK19和甲状腺过氧化物酶表达在甲状腺疾病诊断中的作用[J]. 南方医科大学学报, 2005, 25(06): 678-681.

YANG Qing-xu¹, SHAO Chun-kui², FENG Zhi-ying², HUANG Ben-qiang³, HAN An-jia⁴, XIONG Min⁴, ZHAO Wen-li¹, WU Tong-tong¹. Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases[J]. Journal of Southern Medical University, 2005, 25(06): 678-681.

参考文献

[1] 中山医科大学、同济医科大学.外科病理学[M].第2版,武汉:湖北科学技术出版社,1998.1299-304.
[2] Rapheal SL, Mckeown-Eyssen G, Asa SL. High molecular weight cytokeratin and cytokeratin 19 in the diagnosis of thyroid tumor[J].Mod Pathol, 1994, 7(1):295-300.
[3] Cameron BR, Berean KW. Cytokeratin subtypes in thyroid tumors:immunohistochemical study with emphasis on the follicular variant of papillary carcinoma[J]. J Otolaryngol, 2003, 32(5):319-22.
[4] Shin E, Chung WY, Yang WI, et al. RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation[J]. J Korean Med Sci, 2005, 20(1):98-104.
[5] 张静,丘钜世,陈金培,等.CK19、CK20在甲状腺乳头状癌诊断中的应用价值[J].临床与实验病理学杂志(J Clin Exp Pathol),2002,18(2):181-4.
[6] 方建萍,王雪莉,汤如勇.CK19和PCNA在甲状腺良恶性乳头状增生上皮中的表达[J].同济大学学报(医学版),2003,24(6):478-9Fang JP, Wang XL, Tang RY. Expression of CK19 and PCNA in benign and malignant epithelial papillary hyperplasia of thyroid grand[J]. J Tongji Univ (Med Sci), 2003, 24(6):478-9.
[7] Deleu S, Allory Y, Radulescu A, et al. Characterization of autonomous thyroid adenoma:metabolism, gene expression, and pathology[J]. Thyroid, 2000, 10(2):131-40.
[8] Ros P, Rossi DL, Acebron A, et al. Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis [J]. Biochimie,1999, 81(4):389-96.
[9] Kholova I, Ludvikova M, Ryska A, et al. Diagnostic role of markers dipeptidyl peptidase Ⅳ and thyroid peroxidase in thyroid tumors[J]. Anticancer Res, 2003, 23(2A):871-5.
[10] de Micco C, Kopp F, Vassko V, et al. In situ hybridization and immunohistochemistry study of thyroid peroxidase expression in thyroid tumors[J]. Thyroid, 2000, 10(2):109-15.